2.845
price up icon1.61%   0.045
 
loading
Mei Pharma Inc stock is traded at $2.845, with a volume of 514. It is up +1.61% in the last 24 hours and up +3.83% over the past month. MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
See More
Previous Close:
$2.80
Open:
$2.78
24h Volume:
514
Relative Volume:
0.01
Market Cap:
$18.89M
Revenue:
$105.38M
Net Income/Loss:
$17.78M
P/E Ratio:
-0.6145
EPS:
-4.63
Net Cash Flow:
$-50.48M
1W Performance:
-5.48%
1M Performance:
+3.83%
6M Performance:
-8.81%
1Y Performance:
-52.42%
1-Day Range:
Value
$2.77
$2.78
1-Week Range:
Value
$2.76
$3.01
52-Week Range:
Value
$2.61
$6.9099

Mei Pharma Inc Stock (MEIP) Company Profile

Name
Name
Mei Pharma Inc
Name
Phone
858-369-7100
Name
Address
11455 EL CAMINO REAL, SAN DIEGO, CA
Name
Employee
28
Name
Twitter
@MEI_Pharma
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
MEIP's Discussions on Twitter

Compare MEIP with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
MEIP 2.77 18.89M 105.38M 17.78M -50.48M -4.63
VRTX 447.81 115.74B 10.63B -479.80M -1.35B 13.33
REGN 745.19 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 588.39 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.61 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.50 24.49B 3.30B -501.07M 1.03B 11.54

Mei Pharma Inc Stock (MEIP) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-25-22 Downgrade Jefferies Buy → Hold
Mar-25-22 Downgrade Stifel Buy → Hold
Mar-25-22 Downgrade Wells Fargo Overweight → Equal Weight
Feb-03-22 Initiated Jefferies Buy
Sep-22-20 Initiated Alliance Global Partners Buy
May-29-20 Initiated SunTrust Buy
Dec-20-18 Initiated H.C. Wainwright Buy
Jul-27-18 Upgrade Stifel Hold → Buy
Jul-13-18 Initiated SunTrust Buy
Apr-18-16 Reiterated Wedbush Neutral
Mar-23-15 Downgrade ROTH Capital Buy → Neutral
Dec-18-14 Reiterated ROTH Capital Buy
Oct-16-14 Reiterated ROTH Capital Buy
Jul-08-14 Resumed Brean Capital Buy
Oct-22-13 Reiterated Stifel Buy
Apr-15-13 Initiated Stifel Buy
View All

Mei Pharma Inc Stock (MEIP) Latest News

pulisher
Nov 13, 2024

MEI Pharma Reports Strategic Shift Amid Financial Losses - TipRanks

Nov 13, 2024
pulisher
Nov 12, 2024

MEI Pharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2024 - Marketscreener.com

Nov 12, 2024
pulisher
Nov 12, 2024

MEI Pharma reports Q1 EPS ($1.20) vs. $8.46 last year - TipRanks

Nov 12, 2024
pulisher
Nov 07, 2024

Acute Myeloid Leukemia (AML) Treatment Market in APAC to Grow by USD 305.8 Million from 2024-2028, Driven by High Incidence and AI-Driven Market TransformationTechnavio - Kilgore News Herald

Nov 07, 2024
pulisher
Oct 31, 2024

Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace

Oct 31, 2024
pulisher
Oct 28, 2024

Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews

Oct 28, 2024
pulisher
Oct 27, 2024

Data Readouts At EHA Congress 2021 (APTO, XFOR, GBT, CRIS…) - RTTNews

Oct 27, 2024
pulisher
Oct 25, 2024

Stocks to Watch: MEI Pharma, Hawaiian Electric Industries - MarketWatch

Oct 25, 2024
pulisher
Oct 25, 2024

MEI Shares Rise After Entering Asset Purchase Agreement Valued at Up to $62 Million - MarketWatch

Oct 25, 2024
pulisher
Oct 25, 2024

MEI Pharma postpones special meeting to vote on Infinity deal until July 23 - MSN

Oct 25, 2024
pulisher
Oct 24, 2024

Aardvark Therapeutics, Inc. agreed to acquire rights, title and interest in and to certain assets related to ME-344 from MEI Pharma, Inc. for $62.5 million. - Marketscreener.com

Oct 24, 2024
pulisher
Oct 24, 2024

MEIP (MEI Pharma) Free Cash Flow per Share : $-7.57 (TTM As of Jun. 2024) - GuruFocus.com

Oct 24, 2024
pulisher
Oct 22, 2024

Post Polycythemia Vera Myelofibrosis Market: Holistic - openPR

Oct 22, 2024
pulisher
Oct 14, 2024

Ampio Pharmaceuticals (NYSE:AMPE) Coverage Initiated by Analysts at StockNews.com - Defense World

Oct 14, 2024
pulisher
Oct 09, 2024

MEI Pharma stock hits 52-week low at $2.72 amid market challenges - Investing.com India

Oct 09, 2024
pulisher
Oct 08, 2024

MEI Pharma stock hits 52-week low at $2.72 amid market challenges By Investing.com - Investing.com South Africa

Oct 08, 2024
pulisher
Oct 01, 2024

Acute Myeloid Leukemia Market Trends, Key Drivers, Opportunities, Leading Players And Forecast To 2033 - WhaTech

Oct 01, 2024
pulisher
Sep 25, 2024

Histone Deacetylase 2 Industry Forecast (2024-2034) Under Inflation - Apiculture Market: Report ...

Sep 25, 2024
pulisher
Sep 23, 2024

Myelodysplastic Syndrome Drugs Market Research Explores Size, Market Competitive Landscape, Business Growth... - WhaTech

Sep 23, 2024
pulisher
Sep 22, 2024

Chronic Lymphocytic Leukemia Treatment Market Advancements Highlighted by Comprehensive Analysis, Advanceme... - WhaTech

Sep 22, 2024
pulisher
Sep 20, 2024

Follicular Lymphoma Treatment Market Insights Discussed Regarding Size, Trends, and Overview Report 2024-2033 - WhaTech

Sep 20, 2024
pulisher
Sep 20, 2024

MEI Pharma reviews strategic options amid fiscal changes - Investing.com India

Sep 20, 2024
pulisher
Sep 19, 2024

MEI Pharma confirms continuation of evaluation of strategic alternatives - TipRanks

Sep 19, 2024
pulisher
Sep 19, 2024

MEI Pharma Reports Fiscal Year End 2024 Cash Position - The Bakersfield Californian

Sep 19, 2024
pulisher
Sep 16, 2024

Expanding the Bispecific Antibody Market from CAR-Ts to Drive Follicular Lymphoma's Future | DelveInsight - PR Newswire UK

Sep 16, 2024
pulisher
Sep 15, 2024

LPL Financial (NASDAQ:LPLA) Research Coverage Started at Wells Fargo & Company - Defense World

Sep 15, 2024
pulisher
Sep 15, 2024

Los Angeles Capital Management LLC Reduces Stake in Martin Marietta Materials, Inc. (NYSE:MLM) - Defense World

Sep 15, 2024
pulisher
Sep 02, 2024

Histone Deacetylase Inhibitors Report 2024, Industry Analysis And Overview By 2033 - WhaTech

Sep 02, 2024
pulisher
Aug 23, 2024

Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry - openPR

Aug 23, 2024
pulisher
Aug 17, 2024

MEIP (MEI Pharma) Dividends per Share : $0.00 (TTM As of Mar. 2024) - GuruFocus.com

Aug 17, 2024
pulisher
Aug 16, 2024

Rx Rundown: Vantive, Gilead Sciences, Halda Therapeutics and more - MM+M Online

Aug 16, 2024
pulisher
Aug 12, 2024

MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives - StockTitan

Aug 12, 2024
pulisher
Aug 11, 2024

StockNews.com Initiates Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World

Aug 11, 2024
pulisher
Aug 07, 2024

GreenWood Investors First Half 2024 Letter - Seeking Alpha

Aug 07, 2024
pulisher
Aug 05, 2024

MEI Pharma (MEIP) – Research Analysts’ Recent Ratings Updates - Defense World

Aug 05, 2024
pulisher
Aug 05, 2024

Game-Changing BCL-2 Inhibitors Set to Revolutionize Cancer Treatment Market | DelveInsight - GlobeNewswire

Aug 05, 2024
pulisher
Aug 03, 2024

MEI Pharma announces executive departures and strategic shifts - Investing.com

Aug 03, 2024
pulisher
Aug 02, 2024

MEI Pharma announces executive departures and strategic shifts By Investing.com - Investing.com Canada

Aug 02, 2024
pulisher
Aug 02, 2024

MEI Pharma Explores Strategic Shifts, Leadership Changes - TipRanks

Aug 02, 2024
pulisher
Aug 01, 2024

Non-Hodgkin's Lymphoma Therapeutics Market to Reach USD 18.6 Billion by 2034: Fuelled by New Drugs and Targeted Therapies | Latest Report by TMR - PR Newswire

Aug 01, 2024
pulisher
Jul 30, 2024

MEI Pharma Explores Strategic Options, Halts Drug Development - TipRanks

Jul 30, 2024
pulisher
Jul 27, 2024

Acadian Asset Management LLC Sells 13,658 Shares of MEI Pharma, Inc. (NASDAQ:MEIP) - Defense World

Jul 27, 2024
pulisher
Jul 26, 2024

Biopharma Layoff Tracker 2024: Anokion, GlycoMimetics, Relay and More Cut Staff - BioSpace

Jul 26, 2024
pulisher
Jul 26, 2024

MEI Pharma (NASDAQ:MEIP) Receives New Coverage from Analysts at StockNews.com - Defense World

Jul 26, 2024
pulisher
Jul 26, 2024

StockNews.com Initiates Coverage on Perficient (NASDAQ:PRFT) - Defense World

Jul 26, 2024
pulisher
Jul 24, 2024

MEI Pharma (NASDAQ:MEIP) Downgraded by Brookline Capital Management - Defense World

Jul 24, 2024
pulisher
Jul 24, 2024

State Board of Administration of Florida Retirement System Increases Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World

Jul 24, 2024
pulisher
Jul 24, 2024

Blair William & Co. IL Takes Position in BRC Inc. (NYSE:BRCC) - Defense World

Jul 24, 2024
pulisher
Jul 24, 2024

Avantax Advisory Services Inc. Buys Shares of 8,840 Dimensional World ex U.S. Core Equity 2 ETF (NYSEARCA:DFAX) - Defense World

Jul 24, 2024
pulisher
Jul 23, 2024

MEI Pharma (NASDAQ:MEIP) Downgraded by Laidlaw - Defense World

Jul 23, 2024
pulisher
Jul 23, 2024

Does MEI Pharma Inc (NASDAQ: MEIP) Still Need To Convince Analysts? - Stocks Register

Jul 23, 2024

Mei Pharma Inc Stock (MEIP) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):